News

Featured Articles

Cristalia products with Nemera’s reusable pen injector commercialized in Brazil.

Cristalia’s human growth hormone will be administered with CRISPEN®. Approved by ANVISA1, CRISPEN® is part of Nemera’s state-of-the-art pen injector platform PENDURA AD.

Corporate Events

Brand new state-of-the-art Nemera offices inaugurated in Lyon

12/09/2022

Located in the bio district of Gerland, the BREEAM certified collaborative space will house Nemera’s headquarters & European innovation teams. Morning coffee on the rooftop taking in a view ...

ESG

The Gender Equality Index at Nemera – Year 2021

25/02/2022

L’Index, se calcule à partir de 4 à 5 indicateurs selon que l’entreprise fait moins ou plus de 250 salariés et prend en compte : L’écart de rémunération femmes-hommes, L’é...

Plants

Nemera to build state-of-the-art manufacturing facility in Poland to serve more customers and patients

16/11/2021

Based in Szczecin, this facility extends Nemera’s manufacturing capabilities and will bring more drug delivery device solutions to patients. Following the dynamic growth of the drug delivery devices market, ...

Products

A new ENT device: UniSpray

27/10/2021

We are happy to announce the launch of Unispray, our unidose system primarily for systemic-acting drug administration.

ESG

Nemera joins IPAC-RS as an Associate Member

20/10/2021

Nemera is excited to announce that it has become an Associate Member of the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS)

2021 Products

Symbioze won the Pharmapack Award 2021

30/09/2021

On October 12th, during the Pharmapack Awards Ceremony, a team of industry experts awarded Symbioze, Nemera’s large-volume on-body injector, with the Pharmapack Award in the “Connected Devices and Wearables” category.